


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pierson et al.



Serial No. 10/501,999

Filed: July 20, 2004

For: TREATING STRESS RESPONSE WITH CHEMOKINE
RECEPTOR CCR5 MODULATORS

Art Unit: 1614

Examiner: Fay, Zoreh A.

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT March 16, 2005
EXPRESS MAIL NO. EM660612412US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Yvonne Zebner
DATE March 16, 2005

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney _____ For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3462

Date: March 16, 2005

STATEMENT BY APPLICANT


COMPLETE IF KNOWN

Attorney Docket Number 21067YP

5

Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003


Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		COMPLETE IF KNOWN	
Application Number		10/501,999	
Filing Date		July 20, 2004	
First Named Inventor		Richard N. Pierson III	
Group Art Unit		1614	
Examiner Name		Fay, Zohreh A.	
Sheet	2	of	5
Attorney Docket Number		21067YP	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	11	Seegerer, S., et al., "The Duffy Antigen Receptor for Chemokines is Up-regulated During Acute Renal Transplant Rejection and Crescentic Glomerulonephritis", Kidney Int., Vol. 58, No. 4, pp. 1546-1556 (Oct. 2000)
	12	Seegerer, S., et al., "Expression of the C-C Chemokine Receptor 5 in Human Kidney Diseases", Kidney Int., Vol. 56, No. 1, pp. 52-64 (July 1999)
	13	PUBMED Abstract of: Le, Y., et al., "A New Insight into the Role of 'Old' Chemotactic Peptide Receptors FPR and FPRL1: Down-regulation of Chemokine Receptors CCR5 and CXCR4", Forum (Genova), Vol. 9, No. 4, pp. 299-314 (Oct-Dec 1999)
	14	Zhou, Y., et al., "Impaired Macrophage Function and Enhanced T Cell-Dependent Immune Response in Mice Lacking CCR5, the Mouse Homologue of the Major HIV-1 Coreceptor", Journal of Immunology, Vol. 160, pp. 4018-4025 (1998)
	15	Cascieri, M.A., et al., "The Chemokine/Chemokine-receptor Family: Potential and Progress for Therapeutic Intervention", Chemical Biology, Vol. 4, pp. 420-427 (2000)
	16	Seegerer, S., et al., "Expression of Chemokines and Chemokine Receptors During Human Renal Transplant Rejection", Am. J. of Kidney Diseases, Vol. 37, No. 3, pp. 518-531 (March 2001)
	17	Fischereder M., et al., "CC Chemokine Receptor 5 and Renal-transplant Survival", The Lancet, Vol. 357, pp. 1758-1761, (June 2, 2001)
	18	Strieter, R.M., et al., (Commentary) "Chemokine Receptor Polymorphism in Transplantation Immunology: No Longer Just Important in AIDS", The Lancet, Vol. 357, pp. 1725-1726 (June 2, 2001)
	20	Nadeau, K.C., et al., "Sequential Cytokine Dynamics in Chronic Rejection of Rat Renal Allografts: Roles for Cytokines RANTES and MCP-1", Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 8729-8733 (Sept. 1995)
	21	Belperio, J.A., et al., "The Role of the CC Chemokine, RANTES, in Acute Lung Allograft Rejection", The Journal of Immunology, Vol. 165, pp. 461-472 (2000)
	22	Gröne, H.-J., et al., "Met-RANTES Reduces Vascular and Tubular Damage During Acute Renal Transplant Rejection: Blocking Monocyte Arrest and Recruitment", FASEB J., Vol. 13, pp. 1371-1383 (1999)
	23	Pierson, R.N., et al., "Prolongation of Primate Cardiac Allograft Survival by Treatment with Anti-CD40 Ligand (CD154) Antibody", Transplantation, Vol. 68, No. 11, pp. 1880-1805 (1999)
	24	Netea, M.G., et al., "Circulating Cytokines as Mediators of Fever", Clinical Infectious Diseases, Vol. 31, pp. S178-S184, (2000)
	25	Dinarello, C.A., "Interleukin-1 and Interleukin-1 Antagonism", Blood, Vol. 77, No. 8, pp. 1627-1652 (1991)
	26	Dinarello, C.A., et al., "The Role of Interleukin-1 in Disease", The New England Journal of Medicine, Vol. 328, No. 2, pp. 106-113 (1993)

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003


Substitute for form 1449B/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number	10/501,999
		Filing Date	July 20, 2004
		First Named Inventor	Richard N. Pierson III
		Group Art Unit	1614
		Examiner Name	Fay, Zohreh A.
Sheet	of 5	Attorney Docket Number	21067YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	27	Dinareлло, C.A., "The Interleukin-1 Family: 10 Years of Discovery", The FASEB Journal, Vol. 8, pp. 1314-1325 (1994)
	28	Ikejima, T., et al., "Induction of Human Interleukin-1 by a Product of Staphylococcus aureus Associated with Toxic Shock Syndrome", J. Clin. Invest., Vol. 73, pp. 1312-1320 (1984)
	29	Dinareлло, C.A., "Interleukin-1", Rev. Infect. Disease, Vol. 6, No. 1, pp. 51-94 (1984)
	30	Heinrich, P.C., et al., "Interleukin-6 and the Acute Phase Response", Biochem. J., Vol. 265, pp. 621-636 (1990)
	31	Van Snick, J., "Interleukin-6: An Overview", Annual Review of Immunology, Vol. 8, pp. 253-278 (1990)
	32	Hirano, T., et al., "Biological and Clinical Aspects of Interleukin 6", Immunology Today, Vol. 11, No. 12, pp. 443-449 (1990)
	33	Sehgal, P.B., "Interleukin 6 in Infection and Cancer", Proc. Soc. Exp. Biol. Med., Vol. 195, pp. 183-191 (1990)
	34	Grau, G.E., "Implications of Cytokines in Immunopathology: Experimental and Clinical Data.", Eur. Cytokine Net., Vol. 1, No. 4, pp. 203-210 (1990)
	35	Bauer, J., et al., "Interleukin-6 in Clinical Medicine", Annals of Hematology, Vol. 62, No. 6, pp. 203-210 (1991)
	36	Campbell, I. L., et al., "Essential Role for Interferon-gamma and Interleukin-6 in Autoimmune Insulin-dependent Diabetes in NOD/Wehi Mice", J. Clin. Invest., Vol., 87, pp. 739-742 (1991)
	37	Roodman, G.D., et al., "Interleukin 6 - A Potential Autocrine/Paracrine Factor in Paget's Disease of Bone", J. Clin. Invest., Vol., 89, pp. 46-52 (1992)
	38	Shenkin, A., et al., "The Serum Interleukin 6 Response to Elective Surgery", Lymphokine Res., Vol. 8, No. 2, pp. 123-127 (1989)
	39	Pullicino, E.A., et al., "The Relationship Between the Circulating Concentrations of Interleukin 6 (IL-6), Tumor Necrosis Factor (TNF) and the Acute Phase Response to Elective Surgery and Accidental Injury", Lymphokine Res., Vol. 9, No. 2, pp. 231-238 (1990)
	40	Van Oers, M.H.J., et al., "Interleukin 6 (IL-6) in Serum and Urine of Renal Transplant Recipients", Clin. Exp. Immunol., Vol. 71, pp. 314-319 (1988)
	41	Cerami, A., et al., "The Role of Cachectin/TNF in Endotoxic Shock and Cachexia", Immunology Today, Vol. 9, No. 1 (1998)

Examiner Signature	Date Considered
---------------------------	------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		COMPLETE IF KNOWN			
		Application Number	10/501,999		
		Filing Date	July 20, 2004		
		First Named Inventor	Richard N. Pierson III		
		Group Art Unit	1614		
		Examiner Name	Fay, Zohreh A.		
Sheet	4	of	5	Attorney Docket Number	21067YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	42	Revel, M. et al., "Interferons: Cytokines in Autoimmunity", in Ciba Foundation Symposium 129, (John Wiley, 1987), pp. 223-233
	43	Cohen, J., "Cytokines as Mediators of Graft-versus-host Disease", Bone Marrow Transplantation, Vol. 3, pp. 193-197 (1988)
	44	Tracey, K.J., et al., "Shock and Tissue Injury Induced by Recombinant Human Cachectin", Science, Vol. 234, pp. 470-474 (1986)
	45	Alexander, H.R., et al., "A Recombinant Human Receptor Antagonist to Interleukin 1 Improves Survival after Lethal Endotoxemia in Mice", The Journal of Experimental Medicine, Vol. 173, pp. 1029-1032 (1991)
	46	Doherty, G.M., et al., "Evidence For IFN-gamma as a Mediator of the Lethality of Endotoxin and Tumor Necrosis Factor-alpha", The Journal of Immunology, Vol. 149, No. 5, pp. 1666-1670 (1992)
	47	Wysocka, M., et al., "Interleukin-12 is Required for Interferon-gamma production and Lethality in Lipopolysaccharide-induced Shock in Mice", Eur. J. Immunol., Vol. 25, pp. 672-676 (1995)
	48	Van Deuren, M., et al., "Cytokines and the Response to Infection", Journal of Pathology, Vol. 168, pp. 349-356 (1992)
	49	Bone, R., "The Pathogenesis of Sepsis", Annals of Internal Medicine, Vol. 115, pp. 457-469 (1991)
	50	Starnes, H. F., et al., "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal Escherichia coli Infection and Lethal Tumor Necrosis Factor-alpha Challenge in Mice", The Journal of Immunology, Vol. 145, No. 12, pp. 4185-4191 (1990)
	51	Stevens, D., et al., "Sepsis Syndromes and Toxic Shock Syndromes: Concepts in Pathogenesis and a Perspective of Future Treatment Strategies", Cur. Opin. Infect. Dis., Vol. 6, pp. 374-383 (1993)
	52	Beutler, B., et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", Science, Vol. 229, pp. 869-871 (1985)
	53	Heinzel, F.P., "The Role of IFN-gamma in the Pathology of Experimental Endotoxemia", The Journal of Immunology, Vol. 145, No. 9, pp. 2920-2924 (1990)
	54	Bozza, M., et al., "Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis", J. Exp. Med., Vol. 189, No. 2, pp. 341-346 (1999)
	55	Ohlsson K., et al., "Interleukin-1 Receptor Antagonist Reduces Mortality from Endotoxin Shock", Nature, Vol. 348, pp. 550-552 (1990)
	56	Kelly, J.L., et al., "Is Circulating Endotoxin the Trigger for the Systemic Inflammatory Response Syndrome Seen After Injury?", Annals of Surgery, Vol. 225, No. 5, pp. 530-543 (1997)

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

[illegible]

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003